A survey of the ethical practices of bioscience companies suggests that although most firms feature ethics in their mission statement or code of conduct, fewer than half of the companies surveyed have made any formal efforts to assess how well these approaches are working.
References
Harris, G. As doctor writes prescription, drug company writes a check. The New York Times, June 27 (2004), p.1.
Harris, G. Guilty plea seen for drug maker. The New York Times, July 16 (2004), p. 1.
Lenzer, J. Scandals have eroded US public's confidence in drug industry. Br. Med. J. 329, 247 (2004).
Kaufman, M. Drugs get good ratings, but drug-makers less so. Washington Post, February 26, (2005), p. A3.
Eaton, M.L. Ethics and the Business of Bioscience (Stanford University Press, Stanford, 2004).
Finegold, D. et al. BioIndustry Ethics (Academic Press, New York, 2005).
Acknowledgements
The authors thank Deborah Flynn for help with the survey instrument and excellent administrative support, Steve Casper for his helpful suggestions and Tiffany Sun for advice and editing. Funding for this research was provided by the Seaver Institute, a Los Angeles-based foundation.
Author information
Authors and Affiliations
Supplementary information
Rights and permissions
About this article
Cite this article
Finegold, D., Moser, A. Ethical decision-making in bioscience firms. Nat Biotechnol 24, 285–290 (2006). https://doi.org/10.1038/nbt0306-285
Issue Date:
DOI: https://doi.org/10.1038/nbt0306-285
- Springer Nature America, Inc.
This article is cited by
-
Considerations for applying bioethics norms to a biopharmaceutical industry setting
BMC Medical Ethics (2021)
-
Big Pharma: a former insider’s view
Medicine, Health Care and Philosophy (2013)